Bottu S A Pharmaceutical Import Profile — Morocco (DGFT 2022–2026)

Name: Bottu S A Pharmaceutical Import Records from India — 2 Products, $101.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bottu S A — Pharmaceutical Importer Profile (2026) | 2 Products, $101.3K Trade | TransData Nexus

Bottu S A

Pharmaceutical Importer · Morocco · Advanced Oncology Focus · $101.3K Total Trade · DGFT Verified

Bottu S A is a pharmaceutical importer based in Morocco with a total trade value of $101.3K across 2 products in 1 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Bottu S A sources from 1 verified Indian supplier, with Sp Accure Labs Private Limited accounting for 100.0% of imports.

Bottu S A — Import Portfolio & Supplier Network

Bottu S A import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Bottu S A?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sp Accure Labs Private Limited	$280.5K	10	100.0%

Bottu S A sources from 1 verified Indian supplier across 7 distinct formulations. The sourcing is highly concentrated — Sp Accure Labs Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Bottu S A Import?

Formulation	Value	Ships
Pacli spal l 300 paclitaxel concentrateforsolution for infusion USP 300MG 50ML	$104.3K	3
Pacli spal l 300 paclitaxel concentrateforsolution for infusion usp300mg 50ML	$50.0K	1
L aspal 10000 l asparaginase for injection 10000 IU	$50.0K	1
Metho spal l 1000 methotrexate solutionforinjection bp1000mg 40ML	$38.2K	1
Dact spal 0 5 dactinomycin for injection USP 0 5MG	$19.3K	1
Sp mercap 50 mercaptopurine tablets usp50mg	$11.6K	2
Sptrex 2.5 methotrexate tablets 2.5 MG	$7.1K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vinorelbine	Advanced Oncology	$89.7K	6	2.6%	8
2	Mercaptopurine	Advanced Oncology	$11.6K	2	2.0%	6

Bottu S A imports 2 pharmaceutical products across 1 categories into Morocco totaling $101.3K.

Bottu S A — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Bottu S.A., established in 1952, is a prominent integrated pharmaceutical company headquartered in Casablanca, Morocco. The company is dedicated to ensuring access to essential medicinal drugs for the prevention and treatment of common diseases, thereby enhancing public health and well-being. Bottu S.A. engages in the entire pharmaceutical value chain, encompassing the development, manufacturing, packaging, distribution, and promotion of various products, both under its own brand and other labels.

The company's product portfolio spans multiple therapeutic areas, including the central nervous system, cardiology and metabolism, gastroenterology, infectious diseases and parasitology, respiratory system, rheumatology and traumatology, urogenital system, ophthalmology, dermatology, homeopathy, probiotics, and oncology. Bottu S.A. operates a modern and efficient production facility, adhering to the highest pharmaceutical industry standards. The company has implemented a Quality, Safety, and Environmental Management System compliant with international standards such as ISO 9001, ISO 45001, and ISO 14001, ensuring the development, production, and commercialization of high-quality products.

2Distribution Network

Bottu S.A. maintains a centralized distribution network from its headquarters in Casablanca, strategically located in the industrial district of Ain Sebaa. This location facilitates efficient logistics and distribution across Morocco. The company's distribution capabilities are supported by modern infrastructure and a dedicated workforce, enabling the timely delivery of pharmaceutical products to various regions within the country. While specific details about warehouse locations and logistics operations are not publicly disclosed, Bottu S.A.'s established presence and operational efficiency suggest a robust distribution network capable of meeting national demand.

3Industry Role

Bottu S.A. plays a multifaceted role in Morocco's pharmaceutical supply chain. As a manufacturer, it produces a wide range of pharmaceutical products across various therapeutic categories. Additionally, Bottu S.A. functions as a distributor, ensuring the availability of its products throughout Morocco. The company's integrated approach allows it to maintain control over product quality and distribution, positioning it as a key player in the Moroccan pharmaceutical industry.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Bottu S A

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Bottu S.A.'s sourcing strategy exhibits a high degree of concentration, with a total import value of $101,000 USD from India across eight shipments, primarily consisting of two products: Vinorelbine and Mercaptopurine. This indicates a strategic focus on specific oncology treatments sourced from a single supplier, SP Accure Labs Private Limited, which has provided all these products. While this concentrated sourcing approach may offer benefits such as streamlined procurement processes and potentially favorable pricing, it also introduces risks associated with supplier dependency. Any disruptions in the supplier's operations could significantly impact Bottu S.A.'s ability to meet market demand for these critical oncology medications.

The shipment data reveals a consistent relationship with SP Accure Labs Private Limited, suggesting a stable and reliable supply chain. However, the lack of diversification in sourcing raises concerns about the resilience of Bottu S.A.'s supply chain. To mitigate potential risks, it would be prudent for Bottu S.A. to consider diversifying its supplier base and exploring alternative sources for these essential products.

2Supply Chain Resilience

Bottu S.A.'s supply chain resilience appears to be limited due to its reliance on a single supplier for key oncology medications. The absence of backup suppliers for Vinorelbine and Mercaptopurine means that any disruptions at SP Accure Labs Private Limited could lead to significant challenges in maintaining product availability. Additionally, the lack of formulation diversity in the imported products further constrains the company's ability to adapt to supply chain disruptions.

Importing Pharmaceuticals into Morocco — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Morocco

1Regulatory Authority & Framework

In Morocco, the regulation of pharmaceutical products is overseen by the Ministry of Health, which is responsible for ensuring the safety, efficacy, and quality of medicines available in the country. The legal framework governing pharmaceutical imports is primarily established by Law No. 17-04 on the Code of Medicines and Pharmacy, enacted in 2006. This law outlines the procedures for the registration, manufacturing, distribution, and importation of pharmaceutical products, aiming to protect public health by ensuring that all medicines meet the required standards.

The marketing authorization pathway for Indian generics involves obtaining approval from the Ministry of Health, which includes submitting comprehensive documentation on the product's quality, safety, and efficacy. This process ensures that imported generics meet the same standards as locally manufactured products, facilitating their integration into the Moroccan market. The Ministry of Health evaluates applications based on established criteria, and upon approval, the product is granted a marketing authorization, allowing it to be legally marketed and distributed within Morocco.

2Import Licensing & GMP

Import licensing requirements in Morocco stipulate that pharmaceutical importers must obtain authorization from the Ministry of Health before bringing medicines into the country. This process involves submitting detailed information about the product, including its composition, manufacturing process, and intended use. The Ministry assesses the application to ensure that the imported medicine complies with Moroccan regulations and standards.

Bottu S A — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Bottu S.A.'s focus on importing oncology medications, specifically Vinorelbine and Mercaptopurine, aligns with the growing demand for cancer treatments in Morocco. The decision to import these specific therapeutic areas is likely driven by the high prevalence of cancer and the need for effective treatments. By sourcing these products from India, Bottu S.A. aims to provide essential medications that may not be readily available from local manufacturers, thereby addressing a critical healthcare need in the country

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Bottu S A

What products does Bottu S A import from India?

Bottu S A imports 2 pharmaceutical products across 1 categories. Top imports: Vinorelbine ($89.7K), Mercaptopurine ($11.6K).

Who supplies pharmaceuticals to Bottu S A from India?

Bottu S A sources from 1 verified Indian suppliers. The primary supplier is Sp Accure Labs Private Limited (100.0% of imports, $280.5K).

What is Bottu S A's total pharmaceutical import value?

Bottu S A's total pharmaceutical import value from India is $101.3K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Bottu S A focus on?

Bottu S A imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Bottu S A Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.